Caspers R J, Welvaart K, Verkes R J, Hermans J, Leer J W
Department of Clinical Oncology, University Hospital Leiden, The Netherlands.
Radiother Oncol. 1988 May;12(1):15-23. doi: 10.1016/0167-8140(88)90188-0.
A group of 127 patients with esophageal cancer treated with radiotherapy at different dose levels was retrospectively analysed. It was found that 70.5% of the patients showed improvement of dysphagia and that 54% remained palliated with respect to food passage until their death. The two major prognostic variables with respect to the palliative effect on dysphagia as well as survival were the passage score and the radiation dose. Patients with severe dysphagia (PASS 0 or 1) had a median actuarial DFI and SURV of 3.7 and 6.4 months, respectively, in contrast to 16.0 and 8.7 months for patients who were able to use (semi)solid food (PASS 2 and 3). The median actuarial DFI and SURV of patients treated with a relatively low dose (less than 50 Gy in 5 weeks) were 2.5 and 4.8 months, respectively, compared to 10.1 and 8.3 months, respectively, for patients treated with a relatively high dose.
对一组127例接受不同剂量放疗的食管癌患者进行了回顾性分析。结果发现，70.5%的患者吞咽困难有所改善，54%的患者直至死亡食物通过情况一直保持缓解。与吞咽困难的姑息效果以及生存相关的两个主要预后变量是通过评分和放射剂量。重度吞咽困难（通过评分0或1）的患者精算中位无病生存期（DFI）和生存期（SURV）分别为3.7个月和6.4个月，而能够食用（半）固体食物（通过评分2和3）的患者则分别为16.0个月和8.7个月。相对低剂量（5周内小于50 Gy）治疗的患者精算中位DFI和SURV分别为2.5个月和4.8个月，而相对高剂量治疗的患者则分别为10.1个月和8.3个月。
